STOCK TITAN

Lifecore Biomedical, Inc. - LFCR STOCK NEWS

Welcome to our dedicated page for Lifecore Biomedical news (Ticker: LFCR), a resource for investors and traders seeking the latest updates and insights on Lifecore Biomedical stock.

Lifecore Biomedical, Inc. (symbol: LFCR) is a fully integrated contract development and manufacturing organization (CDMO) specializing in the development, filling, and finishing of complex sterile injectable pharmaceutical products in syringes and vials. The company is renowned for its expertise in manufacturing injectable-grade Hyaluronic Acid, which is utilized in a variety of medical applications, including ophthalmic, orthopedic, and oncology fields.

One of Lifecore's core strengths lies in its comprehensive capabilities that span fermentation, specialty formulation, aseptic filling, and final packaging for FDA-regulated medical devices and drugs. This makes Lifecore a preferred partner for both global and emerging biopharmaceutical and biotechnology companies, helping them bring their innovations to market with high-quality standards.

Founded as part of Landec Corporation, Lifecore has leveraged its robust technological foundation and industry expertise to achieve significant milestones. Recent financial updates indicate a strong focus on liquidity, with the company securing approximately $8 million in non-dilutive, incremental liquidity through various amendments with lenders. As of April 21, 2024, Lifecore reported total debt of $178.9 million and cash reserves of $11.0 million on a pro forma basis.

Lifecore's dedication to innovation is evident in its recent leadership transition, aiming to bolster its strategic direction under new CEO guidance. This move aligns with their efforts to enhance operational efficiency and financial management. For those looking to stay updated on the company's latest developments, Lifecore consistently disseminates news and reports, such as the recent completion of its First Quarter Fiscal 2024 Report on Form 10-Q.

For more information about Lifecore Biomedical and its services, visit their website.

Rhea-AI Summary
Lifecore Biomedical, Inc. (NASDAQ: LFCR) has finalized updated commercial arrangements with long-term customer Alcon, including an 8-year extension of its contract manufacturing agreement, an amendment to its Hyaluronic Acid supply agreement, and a new Storage Services Agreement. The company also received a limited waiver and amendment to its credit agreements with Alcon and BMO, providing additional financial flexibility. Lifecore continues to work on becoming current on its periodic reports, including completing the filing of its Annual Report on Form 10-K for the fiscal year ended May 28, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.5%
Tags
none
-
Rhea-AI Summary
Lifecore Biomedical, Inc. (NASDAQ: LFCR) provided a business update, indicating progress towards completing its Annual Report on Form 10-K for the fiscal year ended May 28, 2023. The Company is actively working on its development portfolio, with 32 projects in development and a pipeline across pre-clinical through late-phase of development. Lifecore is also evaluating potential strategic alternatives, with no set timetable for completion.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.69%
Tags
none
-
Rhea-AI Summary
Lifecore Biomedical, Inc. (NASDAQ: LFCR) announced that the U.S. Department of Justice has declined to prosecute the company for violations of the Foreign Corrupt Practices Act involving its former subsidiary, Yucatan Foods L.P. The company has agreed to pay disgorgement of $406,505 and continue cooperating with ongoing investigations and potential future prosecutions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
Lifecore Biomedical, Inc. receives notice of non-compliance with Nasdaq listing rule
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.99%
Tags
none
-
Rhea-AI Summary
SHL Medical enters co-marketing partnership with Lifecore Biomedical
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.41%
Tags
partnership
-
Rhea-AI Summary
Lifecore Biomedical provides update on delayed filings.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.96%
Tags
none
Rhea-AI Summary
Lifecore Biomedical reports Q4 and FY 2023 results. Q4 revenues increased 12.2% YoY. Net loss from continuing operations in Q4 was $33.8 million. Lifecore segment adjusted EBITDA decreased to $6.1 million. FY 2023 revenues decreased 7.2% YoY. Lifecore segment adjusted EBITDA decreased to $14.7 million. Cash used in operations for FY 2023 was $34.5 million. Cash and cash equivalents as of May 28, 2023, were $19.1 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.8%
Tags
-
Rhea-AI Summary
Lifecore Biomedical, Inc. to host conference call on August 31 to discuss fiscal 2023 Q4 financial results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5%
Tags
-
Rhea-AI Summary
Lifecore Biomedical received a notice from Nasdaq for non-compliance with filing its Annual Report. No immediate effect on stock listing or trading. The company has 60 days to submit a plan to regain compliance. If accepted, they have up to 180 days to file the report.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.73%
Tags

FAQ

What is the current stock price of Lifecore Biomedical (LFCR)?

The current stock price of Lifecore Biomedical (LFCR) is $7.24 as of December 20, 2024.

What is the market cap of Lifecore Biomedical (LFCR)?

The market cap of Lifecore Biomedical (LFCR) is approximately 263.7M.

What does Lifecore Biomedical, Inc. specialize in?

Lifecore Biomedical specializes in the development, filling, and finishing of complex sterile injectable pharmaceutical products, including injectable-grade Hyaluronic Acid.

Who are Lifecore Biomedical's primary clients?

Lifecore partners with global and emerging biopharmaceutical and biotechnology companies, serving multiple therapeutic categories such as ophthalmic, orthopedic, and oncology.

What recent financial update did Lifecore Biomedical release?

Lifecore secured approximately $8 million in non-dilutive, incremental liquidity through amendments with lenders, resulting in $178.9 million in total debt and $11.0 million in cash as of April 21, 2024.

What significant change happened in Lifecore's leadership?

Lifecore commenced a leadership transition by appointing a new CEO to guide their strategic direction and enhance operational efficiency.

What are the two primary product categories Lifecore recognizes revenue from?

Lifecore recognizes revenue from two primary product categories: CDMO services and fermentation.

How long has Lifecore been operating in the CDMO sector?

Lifecore Biomedical has over 40 years of expertise as a CDMO partner, supporting biopharmaceutical and biotechnology companies.

What type of technological capabilities does Lifecore offer?

Lifecore offers comprehensive capabilities including fermentation, specialty formulation, aseptic filling, and final packaging for FDA-regulated products.

Where can I find more information about Lifecore Biomedical?

For more information, you can visit Lifecore Biomedical's official website at www.lifecore.com.

What strategic benefits does the recent liquidity update provide Lifecore?

The liquidity update provides Lifecore with additional financial flexibility to support ongoing operations and future growth initiatives.

What is the symbol for Lifecore Biomedical's common stock?

Lifecore Biomedical's common stock is traded under the symbol LFCR.

Lifecore Biomedical, Inc.

Nasdaq:LFCR

LFCR Rankings

LFCR Stock Data

263.68M
34.83M
5.32%
69.84%
6.7%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States of America
CHASKA